<i>DPYD</i> genotyping and dihydropyrimidine dehydrogenase (DPD) phenotyping in clinical oncology. A clinically focused minireview-Reference-Cited by-同舟云学术

DPYD genotyping and dihydropyrimidine dehydrogenase (DPD) phenotyping in clinical oncology. A clinically focused minireview

Published:2022-09-08 Issue:5 Volume:131 Page:325-346
ISSN:1742-7835
Container-title:Basic & Clinical Pharmacology & Toxicology
language:en
Short-container-title:Basic Clin Pharma Tox

Author:

Paulsen Niels Herluf¹²^ORCID,Vojdeman Fie³,Andersen Stig Ejdrup⁴,Bergmann Troels K.¹⁵^ORCID,Ewertz Marianne⁶,Plomgaard Peter⁷,Hansen Morten Rix¹²⁶⁸^ORCID,Esbech Peter Skov¹^ORCID,Pfeiffer Per⁶⁹,Qvortrup Camilla¹⁰,Damkier Per¹²⁶^ORCID

Affiliation:

1. Department of Clinical Pharmacology Odense University Hospital Odense Denmark

2. Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health University of Southern Denmark Odense Denmark

3. Department of Clinical Biochemistry Holbaek Hospital Holbaek Denmark

4. Clinical Pharmacology Unit Zealand University Hospital Roskilde Denmark

5. Department of Regional Health Research University of Southern Denmark Esbjerg Denmark

6. Department of Clinical Research University of Southern Denmark Odense Denmark

7. Department of Clinical Biochemistry, Rigshospitalet, Department of Clinical Medicine University of Copenhagen Copenhagen Denmark

8. Novo Nordisk Søborg Denmark

9. Department of Oncology Odense University Hospital Odense Denmark

10. Department of Oncology, Rigshospitalet University of Copenhagen Copenhagen Denmark

Funder

Kræftens Bekæmpelse

Publisher

Wiley

Subject

Pharmacology,Toxicology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcpt.13782

Reference39 articles.

1. EMA.5‐Fluorouracil (i.v.) capecitabine and tegafur containing products: Pre‐treatment testing to identify DPD‐deficient patients at increased risk of severe toxicity|European Medicines Agency [Internet]. [cited 2022 Mar 1]. Available from:https://www.ema.europa.eu/en/medicines/dhpc/5-fluorouracil-iv-capecitabine-tegafur-containing-products-pre-treatment-testing-identify-dpd#documents-sectio

2. 5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future

3. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

4. Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III Study

5. Capecitabine as adjuvant treatment for stage III colon cancer;Twelves C;N Engl J Med,2005

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rapid determination of uracil in biological fluids at mercury thin film electrode for early detection of potential 5-fluorouracil toxicity due to dihydropyrimidine dehydrogenase deficiency;Biosensors and Bioelectronics;2024-10

2. Rapid detection of the irinotecan-related UGT1A1 & 5-fluorouracil related DPYD polymorphism by asymmetric polymerase chain reaction melting curve analysis;Clinica Chimica Acta;2024-07

3. First electrochemical bioplatform to assist in personalized 5-fluorouracil chemotherapy;Sensors and Actuators B: Chemical;2024-02

4. Therapeutic Drug Monitoring of 5-Fluorouracil in Head and Neck Cancer Patients: An Interventional Pilot Study;Indian Journal of Medical and Paediatric Oncology;2023-10-25

5. Implementation and clinical benefit of DPYD genotyping in a Danish cancer population;ESMO Open;2023-02